340 related articles for article (PubMed ID: 36297467)
1. Nanoparticle-Based Therapeutic Strategies for Enhanced Pancreatic Ductal Adenocarcinoma Immunotherapy.
Hou W; Yang B; Zhu H
Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297467
[TBL] [Abstract][Full Text] [Related]
2. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
3. Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival.
Urbanova M; Cihova M; Buocikova V; Slopovsky J; Dubovan P; Pindak D; Tomas M; García-Bermejo L; Rodríguez-Garrote M; Earl J; Kohl Y; Kataki A; Dusinska M; Sainz B; Smolkova B; Gabelova A
Biomed Pharmacother; 2023 Sep; 165():115179. PubMed ID: 37481927
[TBL] [Abstract][Full Text] [Related]
4. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
5. A Tumor-Penetrating Nanomedicine Improves the Chemoimmunotherapy of Pancreatic Cancer.
Tong QS; Miao WM; Huang H; Luo JQ; Liu R; Huang YC; Zhao DK; Shen S; Du JZ; Wang J
Small; 2021 Jul; 17(29):e2101208. PubMed ID: 34145747
[TBL] [Abstract][Full Text] [Related]
6. Partial ligand shielding nanoparticles improve pancreatic ductal adenocarcinoma treatment via a multifunctional paradigm for tumor stroma reprogramming.
Zhao T; Zhang R; He Q; Zhou H; Song X; Gong T; Zhang Z
Acta Biomater; 2022 Jun; 145():122-134. PubMed ID: 35381402
[TBL] [Abstract][Full Text] [Related]
7. Advances in Pancreatic Ductal Adenocarcinoma Treatment.
Anderson EM; Thomassian S; Gong J; Hendifar A; Osipov A
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771675
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances in Well-Designed Therapeutic Nanosystems for the Pancreatic Ductal Adenocarcinoma Treatment Dilemma.
Yang XY; Lu YF; Xu JX; Du YZ; Yu RS
Molecules; 2023 Feb; 28(3):. PubMed ID: 36771172
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
Tarannum M; Vivero-Escoto JL
Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
[TBL] [Abstract][Full Text] [Related]
10. The Role of the Microbiome in Pancreatic Cancer.
Miyabayashi K; Ijichi H; Fujishiro M
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139638
[TBL] [Abstract][Full Text] [Related]
11. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
12. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
Panchal K; Sahoo RK; Gupta U; Chaurasiya A
Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
[TBL] [Abstract][Full Text] [Related]
13. Activation of STING in the pancreatic tumor microenvironment: A novel therapeutic opportunity.
Chamma H; Vila IK; Taffoni C; Turtoi A; Laguette N
Cancer Lett; 2022 Jul; 538():215694. PubMed ID: 35489447
[TBL] [Abstract][Full Text] [Related]
14. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic Tumor Microenvironment.
Wang K; He H
Adv Exp Med Biol; 2020; 1296():243-257. PubMed ID: 34185297
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects.
Li KY; Yuan JL; Trafton D; Wang JX; Niu N; Yuan CH; Liu XB; Zheng L
Chronic Dis Transl Med; 2020 Mar; 6(1):6-17. PubMed ID: 32226930
[TBL] [Abstract][Full Text] [Related]
17. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy.
Sarantis P; Koustas E; Papadimitropoulou A; Papavassiliou AG; Karamouzis MV
World J Gastrointest Oncol; 2020 Feb; 12(2):173-181. PubMed ID: 32104548
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in targeted drug delivery for the treatment of pancreatic ductal adenocarcinoma.
Song H; Jiang C
Expert Opin Drug Deliv; 2022 Mar; 19(3):281-301. PubMed ID: 35220832
[TBL] [Abstract][Full Text] [Related]
20. Hydrogel-Based Therapeutics for Pancreatic Ductal Adenocarcinoma Treatment.
Liu J; Wu W; Zhu Q; Zhu H
Pharmaceutics; 2023 Oct; 15(10):. PubMed ID: 37896181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]